Alnylam Pharmaceuticals, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +82.6%
EBITDA: +705.5%
EBIT: +751.9%
EPS: +308.6%
Free cash flow: +950.8%
Operating cash flow: +1680.3%

Forward estimates

Revenue: +62.7%
EBITDA: —
EPS: +128.3%

Three-year CAGR

Revenue: +53.0%
EBITDA: +453.1%
EBIT: +383.6%
Net income: +212.8%
EPS: +209.6%
Free cash flow: +233.1%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.